{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:46:47Z","timestamp":1792457207841,"version":"4.5.0"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,11]]},"abstract":"ABSTRACT<\/jats:title>\n \n E1210 is a first-in-class broad-spectrum antifungal that suppresses hyphal growth by inhibiting fungal glycophosphatidylinositol (GPI) biosynthesis. In the present study, we extend these findings by examining the activity of E1210 and comparator antifungal agents against\n Aspergillus<\/jats:named-content>\n spp. by using the methods of the Clinical and Laboratory Standards Institute (CLSI) and the European Committee for Antimicrobial Susceptibility Testing (EUCAST) to test wild-type (WT) as well as amphotericin B (AMB)-resistant (-R) and azole-R strains (as determined by CLSI methods). Seventy-eight clinical isolates of\n Aspergillus<\/jats:named-content>\n were tested including 20 isolates of\n Aspergillus flavus<\/jats:named-content>\n species complex (SC), 22 of\n A. fumigatus<\/jats:named-content>\n SC, 13 of\n A. niger<\/jats:named-content>\n SC, and 23 of\n A. terreus<\/jats:named-content>\n SC. The collection included 15 AMB-R (MIC, \u22652 \u03bcg\/ml) isolates of\n A. terreus<\/jats:named-content>\n SC and 10 itraconazole-R (MIC, \u22654 \u03bcg\/ml) isolates of\n A. fumigatus<\/jats:named-content>\n SC (7 isolates),\n A. niger<\/jats:named-content>\n SC (2 isolates), and\n A. terreus<\/jats:named-content>\n SC (1 isolate). Comparator antifungal agents included anidulafungin, caspofungin, amphotericin B, itraconazole, posaconzole, and voriconazole. Both CLSI and EUCAST methods were highly concordant for E1210 and all comparators. The essential agreement (EA; \u00b12 log\n 2<\/jats:sub>\n dilution steps) was 100% for all comparisons with the exception of posaconazole versus\n A. terreus<\/jats:named-content>\n SC (EA = 91.3%). The minimum effective concentration (MEC)\/MIC\n 90<\/jats:sub>\n values (\u03bcg\/ml) for E1210, anidulafungin, caspofungin, itraconazole, posaconazole, and voriconazole, respectively, were as follows for each species: for\n A. flavus<\/jats:italic>\n SC, 0.03, \u22640.008, 0.12, 1, 1, and 1; for\n A. fumigatus<\/jats:named-content>\n SC, 0.06, 0.015, 0.12, >8, 1, and 4; for\n A. niger<\/jats:named-content>\n SC, 0.015, 0.03, 0.12, 4, 1, and 2; and for\n A. terreus<\/jats:named-content>\n SC, 0.06, 0.015, 0.12, 1, 0.5, and 1. E1210 was very active against AMB-R strains of\n A. terreus<\/jats:named-content>\n SC (MEC range, 0.015 to 0.06 \u03bcg\/ml) and itraconazole-R strains of\n A. fumigatus<\/jats:named-content>\n SC (MEC range, 0.03 to 0.12 \u03bcg\/ml),\n A. niger<\/jats:named-content>\n SC (MEC, 0.008 \u03bcg\/ml), and\n A. terreus<\/jats:named-content>\n SC (MEC, 0.015 \u03bcg\/ml). In conclusion, E1210 was a very potent and broad-spectrum antifungal agent regardless of\n in vitro<\/jats:italic>\n method applied, with excellent activity against AMB-R and itraconazole-R strains of\n Aspergillus<\/jats:named-content>\n spp.\n <\/jats:p>","DOI":"10.1128\/aac.00570-11","type":"journal-article","created":{"date-parts":[[2011,8,16]],"date-time":"2011-08-16T01:37:29Z","timestamp":1313458649000},"page":"5155-5158","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":74,"title":["In Vitro<\/i>\n Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods"],"prefix":"10.1128","volume":"55","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa 52317"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Duncanson","sequence":"additional","affiliation":[{"name":"Eisai, Woodcliff Lake, New Jersey 07677"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn A.","family":"Messer","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa 52317"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Moet","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa 52317"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa 52317"},{"name":"Tufts University School of Medicine, Boston, Massachusetts 02111"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa 52317"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010080"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2006.06.001"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq279"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.10.1.21"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2010.06.002"},{"key":"e_1_3_2_7_2","unstructured":"CLSI. 2008. M38-A2. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. 2nd edition. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01790.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00536-10"},{"key":"e_1_3_2_10_2","unstructured":"EUCAST. 2010. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.1 April 2010. http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"e_1_3_2_11_2","unstructured":"EUCAST. 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. http:\/\/www.eucast.org\/documents\/technical_notes\/."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/497138"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2010.508469"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1507.090043"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.03050.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-009-0033-7"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.07.026"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00328-10"},{"key":"e_1_3_2_19_2","volume-title":"Proc. 50th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Miyazaki M.","year":"2010","unstructured":"MiyazakiM. HoriiT. HataK. WatanabeM.. 2010. In vitro antifungal activity of E1210: a novel antifungal with activity against clinically important yeasts and moulds, abstr. F1-840. Proc. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September 2010."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00692-10"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.9.4902-4904.2005"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02432-10"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01155-09"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.diagmicrobio.2010.08.013","article-title":"Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiological cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009)","volume":"69","author":"Pfaller M. A.","year":"2011","unstructured":"PfallerM. A. CastanheiraM. MesserS. A. MoetG. J. JonesR. N.. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiological cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69:45\u201350.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00156-08"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/507891"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.09.020"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2003.03481.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M301044200"},{"key":"e_1_3_2_30_2","first-page":"1802","volume-title":"Manual of clinical microbiology","author":"Verweij P. E.","year":"2007","unstructured":"VerweijP. E. BrandtM. E.. 2007. Aspergillus, Fusarium, and other opportunistic moniliaceous fungi, p. 1802\u20131838.In PfallerM. A.(ed.), Manual of clinical microbiology. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2009.09.002"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/525258"},{"key":"e_1_3_2_33_2","volume-title":"Proc. 50th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Watanabe N.","year":"2010","unstructured":"WatanabeN. HoriiT. MiyazakiM. HataK.. 2010. E1210, a new broad-spectrum antifungal, inhibits glycosylphosphatidylinositol (GPI) biosynthesis and effects Candida albicans cell characteristics, abstr. F1-841. Proc. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September 2010."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00570-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00570-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:20:16Z","timestamp":1645467616000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00570-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1128\/AAC.00570-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.00570-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"2011-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-10-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}